CBPE announces strategic combination of Simbec-Orion with Caidya
30-06-2026
View all news
CBPE is pleased to announce the strategic combination of Simbec-Orion with Caidya, a global contract research organisation (CRO).
CBPE is pleased to announce the strategic combination of Simbec-Orion with Caidya, a global contract research organisation (CRO).
The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organisation provides meaningful expertise and execution capabilities in the regions that matter most.
We are pleased to be joining forces with Caidya who shares so much of our common culture. Our combined organisation creates a CRO that combines the intimacy of a specialist partner with the reach of a global development organisation to meet the needs of modern drug development. Together, we will enhance our combined geographic footprint, benefiting Simbec-Orion with enhanced access to the U.S. and Asian markets, and Caidya with greater presence in Europe and in Phase I clinical pharmacology. We are extremely excited to partner with Caidya to create a more complete partner for innovators.
CBPE has been proud to support significant investment in people and the digital transformation of Simbec-Orion, enabling strong growth since 2019. We are confident that joining forces with Caidya represents the ideal next chapter for the business, its people, and its clients. By combining aligned cultures with a more connected development model, sponsors gain a continuous path from First-in-Human through to registration without changing the experienced partner they trust.
This deal was led by Anand Jain (Partner) and supported by Adam Richardson (Partner) and Rachel Milton (Investment Director).
CBPE was advised by Eversheds Sutherland (Legal), Stifel (Corporate Finance) and KPMG (Financial and Tax).
